HEC-88473

N/A

Report date: 2024/11/13 09:32:34

Base Information

Drug NameHEC-88473
Drug Alias NameHEC-88473HEC88473APL-18881
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonistsFibroblast growth factor 21 agonists
TargetsGlucagon-like peptide 1 receptorFibroblast growth factor 21
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2Hepatitis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesDongguan Hec Taigen Biopharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesApollo Therapeutics Group LtdDongguan City Hec Biological Medicine Res And Development Co LtdGuangdong Dongyangguang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsObesityDiabetes Mellitus, Type 2Hepatitis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A